Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has granted De Novo marketing authorization to Avulux's precision optical filter lenses for reducing light sensitivity in patients aged 12 and older with episodic migraine. The lenses — available over the counter with or without a prescription — block specific wavelengths linked to migraine-aggravating light. They're meant to complement, not replace, existing migraine treatments.
The FDA has granted De Novo marketing authorization to Avulux's precision optical filter lenses, creating an entirely new device classification: "light attenuation lenses for migraine-associated light sensitivity." The Class I designation means the lenses can now be marketed specifically for episodic migraine photophobia in patients aged 12 and older — a step up from their previous status as a general wellness product.
The lenses work by selectively blocking light at 480 nm (high-blue range) and 590 nm (red/amber range), wavelengths tied to the activation of light-sensitive retinal cells that can worsen migraine pain. They're available over the counter, with or without a corrective prescription, and are worn like regular glasses. Avulux and the FDA are clear: these lenses are adjunctive tools, not a substitute for medication or other established migraine therapies.
Key Takeaways:
Why it matters: For the millions of migraine sufferers who experience debilitating light sensitivity, this FDA-recognized, non-pharmacologic option offers a new adjunctive tool — particularly valuable for adolescents or patients where medication tolerability is a concern.
